XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
General. (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 5 Months Ended 9 Months Ended
Mar. 16, 2021
USD ($)
shares
Jul. 19, 2021
shares
Apr. 30, 2021
USD ($)
Apr. 19, 2021
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
Sep. 30, 2020
USD ($)
Restructuring Cost and Reserve [Line Items]              
Number of common shares for each preferred share converted 1            
Reverse stock split conversion ratio 4            
Market capitalization amount | $ $ 58,700            
Exercise price per ADs | $ / shares           $ 27.26  
Share-based compensation expense | $           $ 1,011 $ 97
American Depository Shares ADSs [Member] | At the Market Offering Agreement with Cantor Fitzgerald & Co. [Member]              
Restructuring Cost and Reserve [Line Items]              
Aggregate offering price | $     $ 75,000        
Shares issued under agreement         699,806    
Average price of shares issued under agreement | $ / shares         $ 22.75 $ 22.75  
Gross proceeds from sale under agreement | $         $ 15,917    
2015 Plan [Member] | American Depository Shares ADSs [Member]              
Restructuring Cost and Reserve [Line Items]              
Number of shares authorized, increase   540,000          
2015 Plan [Member] | Ordinary Shares [Member]              
Restructuring Cost and Reserve [Line Items]              
Number of shares authorized, increase   10,800,000          
Former Chemomab Security Holders [Member]              
Restructuring Cost and Reserve [Line Items]              
Shareholding percentage immediately following the merger 90.00%            
Number of common shares for each preferred share converted 65,675,904            
Accumulated deficit | $ $ 2,500            
One employee one officer consultant and six Board [Member] | 2015 Plan [Member]              
Restructuring Cost and Reserve [Line Items]              
Share-based compensation expense | $           $ 901  
One employee one officer consultant and six Board [Member] | 2015 Plan [Member]              
Restructuring Cost and Reserve [Line Items]              
Options to purchase ADs       122,404      
Exercise price per ADs | $ / shares       $ 27.26      
One employee one officer consultant and six Board [Member] | 2015 Plan [Member] | Minimum [Member]              
Restructuring Cost and Reserve [Line Items]              
Share based payment options vesting period       3 years      
One employee one officer consultant and six Board [Member] | 2015 Plan [Member] | Maximum [Member]              
Restructuring Cost and Reserve [Line Items]              
Share based payment options vesting period       4 years      
One employee one officer consultant and six Board [Member] | 2015 Plan [Member] | American Depository Shares ADSs [Member]              
Restructuring Cost and Reserve [Line Items]              
Options to purchase ADs       122,404      
Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]              
Restructuring Cost and Reserve [Line Items]              
Number of ordinary shares represented by each ADS (in shares) 20            
Number of ADS issued and outstanding after the merger 12.86            
Number of shares diluted after the merger 8,078,727            
Number of shares after merger for each share of Chemomab 9,003,357